KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
AcquisitionsAmortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Dividends Paid - CommonFree Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Alto Ingredients (ALTO) Asset Writedowns and Impairment (2017 - 2025)

Historic Asset Writedowns and Impairment for Alto Ingredients (ALTO) over the last 14 years, with Q3 2025 value amounting to -$3000.0.

  • Alto Ingredients' Asset Writedowns and Impairment rose 8750.0% to -$3000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $26.0 million, marking a year-over-year increase of 29609.93%. This contributed to the annual value of $24.8 million for FY2024, which is 27882.03% up from last year.
  • Latest data reveals that Alto Ingredients reported Asset Writedowns and Impairment of -$3000.0 as of Q3 2025, which was up 8750.0% from $16000.0 recorded in Q2 2025.
  • Alto Ingredients' Asset Writedowns and Impairment's 5-year high stood at $24.8 million during Q4 2024, with a 5-year trough of -$253000.0 in Q3 2022.
  • Moreover, its 5-year median value for Asset Writedowns and Impairment was $574000.0 (2023), whereas its average is $2.7 million.
  • As far as peak fluctuations go, Alto Ingredients' Asset Writedowns and Impairment surged by 1045555.56% in 2021, and later tumbled by 9815.79% in 2022.
  • Quarter analysis of 5 years shows Alto Ingredients' Asset Writedowns and Impairment stood at $1.9 million in 2021, then skyrocketed by 152.58% to $4.8 million in 2022, then rose by 24.4% to $6.0 million in 2023, then surged by 315.63% to $24.8 million in 2024, then tumbled by 100.01% to -$3000.0 in 2025.
  • Its Asset Writedowns and Impairment stands at -$3000.0 for Q3 2025, versus $16000.0 for Q2 2025 and $1.2 million for Q1 2025.